ArticleNature medicine2018
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
4 registry-linked trialsAbstract readClinical Trial, Phase I
In one paragraph
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 833 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
833citing papers in PubMed, 3 pooled it
57.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT06735495 phase1 / phase2recruitingnot on this mapstarted 2024, after this paper: background citation
The Safety and Efficacy of CD19 & CD22 Bispecific CAR T Cells in Treating Relapsed / Refractory B Cell Hematological Tumors
A Phase 1 Multicenter, Open Label Trial Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
NCT07319676 phase1 / phase2recruitingnot on this mapstarted 2026, after this paper: background citation
Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas
NCT07502118 phase2 / phase3recruitingnot on this mapstarted 2025, after this paper: background citation
An Open-Label, Multicenter Phase 2-3 Clinical Study of Anti-CD19 Chimeric Antigen Receptor T Cells (Talikabtagene Autoleucel) in Patients With Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Who cites it
833 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,320 citations in OpenAlex.
- Outcomes of Wild Type and TP53-Mutated B Cell Malignancy Patients Receiving CAR-T Cell Therapy: A Systematic Review and Meta-Analysis.Journal of cellular and molecular medicine · 2025Pooled it
- Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies.Frontiers in immunology · 2025Pooled it
- Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis.Annals of medicine · 2024Pooled it
- Comparative efficacy and long-term survival of CD19/22 versus CD19 CAR-T immunotherapy in Relapsed/Refractory B-ALL with TP53 alterations.Journal of translational medicine · 2026Trial
- Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma.Journal of translational medicine · 2025Trial
- CAR-T-centered sequential therapy: current status, challenges, and future clinical perspectives.Journal of hematology & oncology · 2026Review
- Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells.Cancer immunology research · 2026Article
- Multi-dimensional orchestration of binders for improved CAR-T immunotherapy.Cancer letters · 2026Review
- Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma.BMC cancer · 2026Article
- A Festschrift Celebrating Dr. Dimiter Stanchev Dimitrov: Antibodies, Innovation, and Impact on Infectious Disease and Cancer Research.Antibodies (Basel, Switzerland) · 2026Article
- B Cell Aplasia Following CAR T Cell Therapy: Incidence, Kinetics, Prognostic Implications, and Clinical Management.Cancers · 2026Review
- Antigen Pressure, Clonal Evolution, and Lineage Plasticity in B-Cell Acute Lymphoblastic Leukemia: Resistance Biology in the Immunotherapy Era.Current hematologic malignancy reports · 2026Review
- Article
- FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia.Leukemia · 2026Article
- Biocompatible Glycoconjugation Enables Sensitive In Vivo Cell Tracking by PET/CT.Journal of medicinal chemistry · 2026Article
- A roadmap for systematic humanization of a chimeric antigen receptor: preclinical validation of a humanized CD22 scFv as a model.Experimental hematology · 2026Article
- Single-cell genomics links targeted functional manipulations to efficacy-associated chromatin signatures in CAR T cells.Research square · 2026Article
- Bispecific CAR T and CAR NK cells in dual-threat immunotherapy: opportunities and challenges.Molecular biology reports · 2026Review
- CAR T cells for pediatric CNS tumors: Clinical experience and reverse translational opportunities.Molecular therapy. Oncology · 2026Review
- CD22 as a Target for Hematological Malignancies and Autoimmune Diseases.International journal of molecular sciences · 2026Review
773 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 6 institutions in 1 country.
Terry J FryPediatric Oncology Branch, Center for Cancer Research, National Institutes of Health (NIH), Bethesda, Maryland, USA.ORCID 0000-0001-8044-5226
Nirali N ShahPediatric Oncology Branch, Center for Cancer Research, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Rimas J OrentasPediatric Oncology Branch, Center for Cancer Research, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Maryalice Stetler-StevensonLaboratory of Pathology, Center for Cancer Research, NIH, Bethesda, Maryland, USA.
Constance M YuanLaboratory of Pathology, Center for Cancer Research, NIH, Bethesda, Maryland, USA.
Sneha RamakrishnaPediatric Oncology Branch, Center for Cancer Research, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Pamela WoltersPediatric Oncology Branch, Center for Cancer Research, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Staci MartinPediatric Oncology Branch, Center for Cancer Research, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Cindy DelbrookPediatric Oncology Branch, Center for Cancer Research, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Bonnie YatesPediatric Oncology Branch, Center for Cancer Research, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Haneen ShalabiPediatric Oncology Branch, Center for Cancer Research, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Thomas J FountainePediatric Oncology Branch, Center for Cancer Research, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Jack F ShernPediatric Oncology Branch, Center for Cancer Research, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Robbie G MajznerDepartment of Pediatrics, Stanford University, Stanford, California, USA.
David F StroncekDepartment of Transfusion Medicine, NIH Clinical Center, NIH, Bethesda, Maryland, USA.
Marianna SabatinoDepartment of Transfusion Medicine, NIH Clinical Center, NIH, Bethesda, Maryland, USA.
Yang FengCancer and Inflammation Program, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Dimiter S DimitrovCancer and Inflammation Program, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Ling ZhangPediatric Oncology Branch, Center for Cancer Research, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Sang NguyenPediatric Oncology Branch, Center for Cancer Research, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Haiying QinPediatric Oncology Branch, Center for Cancer Research, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Boro DropulicLentigen Corporation, Gaithersburg, Maryland, USA.
Daniel W LeePediatric Oncology Branch, Center for Cancer Research, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Crystal L MackallDepartment of Pediatrics and Standford Cancer Center, Stanford University, Stanford, California, USA.ORCID 0000-0003-0359-9023
National Institutes of Health · USCenter for Cancer Research · USNational Cancer Institute · USNational Institutes of Health Clinical Center · USStanford University · USLentigen Technology (United States) · US
Funding
Genomic dissection of tumor heterogeneity and progressionZIABC011734 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHERN, JOHN · 2016 to 2025
$6.8MAdoptive T cell Therapy for Pediatric LeukemiaZIABC011565 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FRY, TERRY · 2014 to 2018
$5.2MOptimizing the graft versus leukemia effect for pediatric ALLZIABC011295 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FRY, TERRY · 2010 to 2018
$4.8MDevelopment of novel cell and gene therapiesZIACL002120 · CLC · CLINICAL CENTER · PI STRONCEK, DAVID · 2009 to 2025
$0kIntramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC011295
Abstract
Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent effects in relapsed and/or refractory pre-B cell acute lymphoblastic leukemia (B-ALL), but antigen loss is a frequent cause of resistance to CD19-targeted immunotherapy. CD22 is also expressed in most cases of B-ALL and is usually retained following CD19 loss. We report results from a phase 1 trial testing a new CD22-targeted CAR (CD22-CAR) in 21 children and adults, including 17 who were previously treated with CD19-directed immunotherapy. Dose-dependent antileukemic activity was observed, with complete remission obtained in 73% (11/15) of patients receiving ≥1 × 10
Indexed as
ImmunotherapyAdolescentAdultAntigens, CD19ChildCytokinesHumansPrecursor B-Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenRemission InductionSialic Acid Binding Ig-like Lectin 2Young AdultAntigens, CD19CD19 molecule, humanCD22 protein, humanCytokinesReceptors, Chimeric AntigenSialic Acid Binding Ig-like Lectin 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT06735495ClinicalTrials.gov
NCT06879340ClinicalTrials.gov
NCT07319676ClinicalTrials.gov
NCT07502118ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.